Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer Maynard MA; Ohh MAm J Nephrol 2004[Jan]; 24 (1): 1-13The development of hereditary von Hippel-Lindau (VHL) disease and the majority of sporadic kidney cancers are due to the functional inactivation of the VHL gene. The product of the VHL gene, pVHL, in association with elongins B and C, cullin 2, and Rbx1 form an E3 ubiquitin-ligase complex VEC that targets the alpha subunits of hypoxia-inducible factor (HIF) for ubiquitination. Ubiquitin-tagged HIF-alpha proteins are subsequently degraded by the common 26S proteasome. pVHL functions as the substrate-docking interface that specifically recognizes prolyl-hydroxylated HIF-alpha. This hydroxylation occurs only in the presence of oxygen or normoxia. Thus, under hypoxia, HIF-alpha subunits are no longer subjected to degradation and are thereby able to dimerize with the common and constitutively stable beta subunits. The heterodimeric HIFs upregulate a myriad of hypoxia-inducible genes, triggering our physiologic response to hypoxia. Inappropriate accumulations of HIF-alpha in VHL disease are believed to contribute to the pathogenesis via the upregulation of several of these HIF target genes. Our current molecular understanding of the roles of HIF and pVHL in the development of VHL-associated clear-cell renal cell carcinoma (CC-RCC) is the focus of this review.|Adenocarcinoma, Clear Cell/*metabolism/physiopathology[MESH]|Clinical Trials as Topic[MESH]|DNA-Binding Proteins/*physiology[MESH]|Genes, Tumor Suppressor/*physiology[MESH]|Humans[MESH]|Hypoxia-Inducible Factor 1[MESH]|Hypoxia-Inducible Factor 1, alpha Subunit[MESH]|Kidney Neoplasms/*metabolism/physiopathology[MESH]|Nuclear Proteins/*physiology[MESH]|Transcription Factors/physiology[MESH]|Tumor Suppressor Proteins/*physiology[MESH]|Ubiquitin-Protein Ligases/*physiology[MESH]|Von Hippel-Lindau Tumor Suppressor Protein[MESH]|von Hippel-Lindau Disease/*metabolism/physiopathology[MESH] |
